Patient receipt and understanding of written information provided with isotretinoin and estrogen prescriptions

Journal of General Internal Medicine

Volumn 22, Issue 1, 2007, Pages 98-101

  Allen LaPointe, Nancy M ^a   Pappas, Paul ^a   Deverka, Patricia ^b   Anstrom, Kevin J ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Drug information; Medication guide; Package insert; Patient education

Indexed keywords

AMNESTEEM; CONJUGATED ESTROGEN; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ISOTRETINOIN; SOTRET; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MONITORING; FEE; FEMALE; HEALTH SURVEY; HOSPITAL ORGANIZATION; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT EDUCATION; PRESCRIPTION; QUESTIONNAIRE; RISK ASSESSMENT; WRITTEN LANGUAGE; DRUG LABELING; MIDDLE AGED;

ADULT; DERMATOLOGIC AGENTS; DRUG LABELING; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; PATIENT EDUCATION; PRESCRIPTIONS, DRUG; QUESTIONNAIRES;

EID: 34248594709     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0109-4     Document Type: Article

References (12)

1. Marwick C. MedGuide: at last, a long-sought opportunity for patient education about prescription drugs. JAMA. 1997;277:949-50.
2. Marwick C. Provision of prescription drug info mandated. JAMA. 1996;276(12):935.
3. 21 CFR 310.515. US Food and Drug Administration web site. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310. 515. Accessed 8 May 2006.
4. 21 CFR 208.1. US Food and Drug Administration Web site. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=208.1. Accessed 8 May 2006.
5. Center for Drug Evaluation and Research. Patient Labeling and Risk Communication. Center for Drug Evaluation and Research web site. Available at: http://www.fda.gov/cder/Offices/ODS/labeling.htm. Accessed 8 May 2006.
6. Zeger SL, Liang KY, Self SG. The analysis of binary longitudinal data with time-independent co-variates. Biometrika. 1985;72:31-8.
7. Buck ML. Providing patients with written medication information. Ann Pharmacother. 1998;32:962-9.
8. Weingart SN, Gandhi TK, Seger AC, et al. Patient-reported medication symptoms in primary care. Arch Intern Med. 2005;165:234-40.
9. Brinker A. Pregnancy and pregnancy rates in association with isotretinoin (Accutane). J Am Acad Dermatol. 2002;47:798-9.
10. US Food and Drug Administration. Overview of the 1st year of the isotretinoin Risk Management Program (RMP) (Jan 29, 2004). US Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/04/ briefing/4017B1-06%20Accutance%20Overview%20Section%20C%20Tab%201.htm. Accessed 8 May 2006.
11. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program. Arch Dermatol. 2005;141:563-9.
12. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-40.